Baird Reiterates Outperform on Biomarin Pharmaceutical, Maintains $127 Price Target
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Joel Beatty has reiterated his 'Outperform' rating on Biomarin Pharmaceutical (NASDAQ:BMRN) and maintained a price target of $127.
June 30, 2023 | 1:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Baird analyst Joel Beatty has reiterated his 'Outperform' rating on Biomarin Pharmaceutical, maintaining a price target of $127.
The reiteration of the 'Outperform' rating and the maintenance of the price target by Baird analyst Joel Beatty indicates a positive outlook for Biomarin Pharmaceutical. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100